- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03503331
UAB Alzheimer's Disease Center Core Cohort - Imaging Substudy (PiB ADC)
June 29, 2023 updated by: Jonathan E McConathy, University of Alabama at Birmingham
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB Alzheimer's Disease Center cohort.
Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
Study Overview
Detailed Description
The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic amyloid deposition using the PET tracer [C-11]PiB in participants in the UAB-ADC cohort.
The amount and distribution of [C-11]PiB in the brain will be correlated to demographic, clinical, genetic, and biospecimen data acquired through the separate ongoing UAB-ADC study.
Assessment of interactions between race and vascular risk factors, brain amyloid levels measured with [C-11]PiB-PET, and cognitive status will be the primary outcome of this imaging study.
As a secondary aim, the investigators will assess the ability of the early flow frames from [C-11]PiB-PET and brain volumetric measurements with MRI to serve as a marker of neuronal injury and to predict cognitive status in conjunction with the amyloid-PET results.
Study Type
Interventional
Enrollment (Estimated)
160
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: April Riddle
- Phone Number: 2059346504
- Email: ariddle@uabmc.edu
Study Contact Backup
- Name: Marianne Vetrano
- Phone Number: 205-934-4080
- Email: mvetrano@uabmc.edu
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- Recruiting
- University of Alabama at Birmingham Medical Center
-
Principal Investigator:
- Jonathan McConathy, MD, PhD
-
Contact:
- Jonathan McConathy, MD
- Phone Number: 205-996-7115
- Email: jmcconathy@uabmc.edu
-
Sub-Investigator:
- Bag Asim, MD
-
Sub-Investigator:
- Bhambhvani Pradeep, MD
-
Sub-Investigator:
- Choudhary Gagandeep, MD
-
Sub-Investigator:
- Geldmacher David, MD
-
Sub-Investigator:
- Lapi Suzanne, PhD
-
Sub-Investigator:
- Jeffers Charlotte Denise, RPh
-
Sub-Investigator:
- Natelson Marissa, MD
-
Sub-Investigator:
- Roberson Erik, MD, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
50 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- 1. Enrollment in the UAB-ADC study under a separate IRB-approved research protocol (IRB-300000169).
2. Negative urine or serum B-hCG test within 2 days of [C-11]PiB administration in women of child bearing potential. Women who are post-menopausal with at least 1 year since last menses or documented surgical sterilization will not require pregnancy testing.
Exclusion Criteria:
- Meets any exclusion criteria for the UAB-ADC study (IRB-300000169).
- Inability or contraindication for undergoing MRI and/or PET imaging
- Inability to participate in the imaging studies due to severity of dementia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [C-11]PiB-PET/MRI
All participants in this study will undergo an amyloid-PET imaging using the tracer [C-11]PiB with a simultaneous PET/MRI system.
The [C-11]PiB dosage is 300-670 MBq (8 - 18 mCi) given intravenously, and the PET/MRI imaging time is approximately 60 min.
|
All study participants will undergo brain imaging with [C-11]PiB-PET/MRI.
[C-11]PiB is a PET imaging agent used primarily to measure the amount of abnormal protein (called beta-amyloid) in the brain.
The investigator will also use this tracer to evaluate regional cerebral blood flow.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of pathological beta-amyloid in the brain
Time Frame: 5 years
|
The amount of pathological beta-amyloid in the brains of study participants will be measured with [C-11]PiB-PET/MRI using standardized uptake value ratios (SUVRs) derived from the PET images.
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Jonathan McConathy, MD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 20, 2018
Primary Completion (Estimated)
April 1, 2026
Study Completion (Estimated)
April 1, 2026
Study Registration Dates
First Submitted
February 26, 2018
First Submitted That Met QC Criteria
April 18, 2018
First Posted (Actual)
April 19, 2018
Study Record Updates
Last Update Posted (Actual)
July 3, 2023
Last Update Submitted That Met QC Criteria
June 29, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB-300001005
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on [C-11]PiB-PET/MRI
-
Mayo ClinicEnrolling by invitationParkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic AphasiaUnited States
-
Mayo ClinicNational Institute on Aging (NIA)RecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Amnestic Mild Cognitive Disorder | Atypical Alzheimer's Disease | Logopenic Progressive Aphasia (LPA) | Posterior Cortical Atrophy (PCA) | Amnestic Disorder | Amnestic SymptomsUnited States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health... and other collaboratorsRecruitingCardiomyopathy | Amyloidosis, PrimaryUnited States
-
Avid RadiopharmaceuticalsGeneral Electric; American College of Radiology Imaging NetworkCompletedAlzheimer's DiseaseUnited States
-
Washington University School of MedicineCompletedAlzheimer Disease | Alzheimer DementiaUnited States
-
Mayo ClinicCompletedPosterior Cortical Atrophy (PCA) | Atypical Alzheimers Disease | Logopenic Variant of Primary Progressive Aphasia (LPA)United States
-
Dana-Farber Cancer InstituteMassachusetts General Hospital; Beth Israel Deaconess Medical CenterCompletedProstate CancerUnited States
-
Michael C Roarke, MDCompleted
-
Irene BurgerCompletedProstate CancerSwitzerland
-
Università Vita-Salute San RaffaeleIRCCS San Raffaele; Associazione Italiana per la Ricerca sul CancroNot yet recruitingBreast Cancer Female | Lobular Breast Carcinoma | Luminal A Breast Cancer | PET/MRI | Axillary Lymphadenopathy